In Vitro and In Vivo Antifungal Activity of AmBisome Compared to Conventional Amphotericin B and Fluconazole against Candida auris

Antimicrob Agents Chemother. 2021 May 18;65(6):e00306-21. doi: 10.1128/AAC.00306-21. Print 2021 May 18.

Abstract

Antifungal activity of AmBisome against Candida auris was determined in vitro and in vivo AmBisome showed MIC50 and MIC90 values of 1 and 2 μg/ml, respectively. Unlike conventional amphotericin B, significant in vivo efficacy was observed in the AmBisome 7.5 mg/kg treatment group in survival and reduction of kidney tissue fungal burden compared to the untreated group. Our data show that AmBisome has significant antifungal activity against C. auris infection in vitro and in vivo.

Keywords: AmBisome; Candida auris; conventional amphotericin B; fluconazole; mouse models; multidrug resistant; susceptibility testing.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B* / pharmacology
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida
  • Candidiasis, Invasive
  • Fluconazole* / pharmacology
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B
  • Fluconazole

Supplementary concepts

  • Candida auris infection